Everest Medicines wins China NMPA approval for CARDAMYST nasal spray
Everest Medicines says China’s NMPA approved CARDAMYST (etripamil) nasal spray to convert acute symptomatic PSVT to sinus rhythm in adults, providing an out-of-hospital, self-administered option.
Everest Medicines received China NMPA approval for CARDAMYST (etripamil) nasal spray for the conversion of acute symptomatic PSVT to sinus rhythm in adults, giving patients an out-of-hospital, self-administered option.